Coya Therapeutics, Inc. (COYA) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$3.40

From 52W high−52.69%

Volume195385.00

Market cap$72.25M

P/E (TTM)—

P/S (TTM)9.0x

Div yield—

Key dataNov 4, 2026

Open

$3.40

From 52W high

−52.69%

Volume

195385.00

Market cap

$72.25M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

P/E (TTM)

—

RSI (14)

20.9

MomentumView details →

1D Return

−0.96%

YTD Return

−46.55%

SummaryUpdated Jun 1, 2026

Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company founded in 2020 and headquartered in Houston, Texas. The company went public in December 2022 and focuses on developing innovative therapeutic treatments that harness the power of regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic diseases. Coya represents a relatively new entrant in the specialized field of immunotherapy, specifically targeting diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia through novel approaches involving cellular therapy and biologics.

Ask drillr about Coya Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.3x

EV/Sales

3.6x

P/S (TTM)

9.0x

P/B (TTM)

1.7x

ProfitabilityView details →

Gross Margin

99.91%

Net Margin

−270.22%

EBITDA Margin

−275.22%

ROE (TTM)

−50.07%

ROA (TTM)

−45.81%

Asset Turnover

0.16x

GrowthView details →

Revenue YoY

+1793.76%

EPS YoY

+13.71%

FCF YoY

—

Revenue CAGR 3Y

+15.06%

EPS CAGR 3Y

−29.59%

EBITDA YoY

−0.76%

MomentumView details →

1D Return

−0.96%

YTD Return

−46.55%

1Y Return

−46.28%

RSI (14)

20.9

vs 50D SMA

−31.16%

vs 200D SMA

−32.99%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

13.40x

Quick Ratio

13.40x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.28

EPS Surprise

19.01%

Beats (12Q)

3/12

Next Q EPS Est

−$0.37

Avg Surprise (4Q)

−146.95%

Rev Surprise

70.67%

Financials snapshotView financials →

Revenue (TTM)

8.02M

Net Income (TTM)

−21.67M

Op. CF (TTM)

−13.68B

Next earningsNov 11, 2026 →

Latest newsMore news →

Coya Therapeutics reported its financial results for the second quarter of 2026 and provided a corporate update.86d ago

Similar companies

Nutriband Inc.NTRB China Regenerative Medicine International Limited08158.HK MediciNova, Inc.MNOV OKYO Pharma LimitedOKYO Acrivon Therapeutics, Inc. Common StockACRV Corbus Pharmaceuticals Holdings, Inc.CRBP Find similar companies →

Latest newsMore news →

Coya Therapeutics announced plans to initiate an open-label extension of its Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis, in response to requests from trial investigators.22d ago Coya Therapeutics reported its financial results for the second quarter of 2026 and provided a corporate update.86d ago